NASDAQ:CTOR

Citius Oncology Q2 2025 Earnings Results & Report

Citius Oncology logo
$0.56 +0.01 (+1.79%)
Closing price 04:00 PM Eastern
Extended Trading
$0.55 -0.01 (-0.97%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Citius Oncology missed analyst earnings expectations in its Q2 2025 results, released May 14, 2025. The company reported EPS of -$0.11 versus the -$0.09 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Citius Oncology EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.09
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 5 quarters

Citius Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.74 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Citius Oncology's Q4 2026 earnings is estimated for Thursday, December 17, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, December 23, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Citius Oncology Q2 2025 Earnings FAQ

Citius Oncology (NASDAQ:CTOR) reported earnings of -$0.11 per share for Q2 2025, missing the consensus estimate of -$0.09. The report was announced on Wednesday, May 14, 2025.

Citius Oncology's next earnings date is estimated for Thursday, December 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Citius Oncology on the company's earnings history page.

Citius Oncology Earnings Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More Citius Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Citius Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Oncology and other key companies, straight to your email.

About Citius Oncology

Citius Oncology (NASDAQ:CTOR) is a biopharmaceutical company focused on developing and commercializing oncology therapies. Its lead product is LYMPHIR (denileukin diftitox-cxdl), an immunotherapy approved in the United States for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

LYMPHIR targets cells expressing the interleukin-2 receptor and is intended to treat certain forms of CTCL, a rare non-Hodgkin lymphoma that affects the skin. The company’s commercial activities are centered on making the therapy available to eligible patients in the U.S.

Citius Oncology became a publicly traded company following a business combination involving Citius Pharmaceuticals’ oncology subsidiary and TenX Keane Acquisition. Leonard Mazur, a co-founder and longtime executive of Citius Pharmaceuticals, has served as Citius Oncology’s chief executive officer.

View Citius Oncology Profile